Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioHarvest Sciences Inc. stock logo
BHST
BioHarvest Sciences
$6.35
+1.6%
$6.17
$6.25
$7.38
$104.30M0.817,233 shs9,949 shs
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
$5.87
+0.9%
$5.39
$4.09
$17.24
$125.48M0.81284,623 shs44,679 shs
Metacrine, Inc. stock logo
MTCR
Metacrine
$0.58
$0.57
$0.30
$0.59
$24.75M-0.73225,834 shs83,889 shs
XBiotech Inc. stock logo
XBIT
XBiotech
$2.91
-1.7%
$3.02
$2.65
$8.32
$88.72M0.9874,384 shs36,260 shs
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioHarvest Sciences Inc. stock logo
BHST
BioHarvest Sciences
+1.60%+4.10%+1.44%+22.35%+634,999,900.00%
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
+0.86%+1.38%+4.26%-25.51%-50.80%
Metacrine, Inc. stock logo
MTCR
Metacrine
0.00%0.00%0.00%0.00%0.00%
XBiotech Inc. stock logo
XBIT
XBiotech
-1.69%+1.39%+1.04%-6.43%-62.74%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BioHarvest Sciences Inc. stock logo
BHST
BioHarvest Sciences
N/AN/AN/AN/AN/AN/AN/AN/A
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
3.8474 of 5 stars
3.41.00.04.73.62.50.0
Metacrine, Inc. stock logo
MTCR
Metacrine
N/AN/AN/AN/AN/AN/AN/AN/A
XBiotech Inc. stock logo
XBIT
XBiotech
0.645 of 5 stars
0.01.00.00.03.12.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioHarvest Sciences Inc. stock logo
BHST
BioHarvest Sciences
3.00
Buy$13.67115.22% Upside
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
2.80
Moderate Buy$17.25193.87% Upside
Metacrine, Inc. stock logo
MTCR
Metacrine
0.00
N/AN/AN/A
XBiotech Inc. stock logo
XBIT
XBiotech
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest MTCR, BHST, ENTA, and XBIT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/5/2025
BioHarvest Sciences Inc. stock logo
BHST
BioHarvest Sciences
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$15.00
4/8/2025
BioHarvest Sciences Inc. stock logo
BHST
BioHarvest Sciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$14.00 ➝ $14.00
(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioHarvest Sciences Inc. stock logo
BHST
BioHarvest Sciences
$27.70M3.76N/AN/A($1.08) per share-5.88
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
$64.46M1.95N/AN/A$5.24 per share1.12
Metacrine, Inc. stock logo
MTCR
Metacrine
N/AN/AN/AN/A$1.36 per shareN/A
XBiotech Inc. stock logo
XBIT
XBiotech
$4.01M22.12N/AN/A$7.19 per share0.40
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioHarvest Sciences Inc. stock logo
BHST
BioHarvest Sciences
-$12.56M-$0.50N/AN/AN/A-76.65%N/A-85.16%5/29/2025 (Estimated)
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
-$116.04M-$4.54N/AN/AN/A-157.57%-75.53%-27.30%8/4/2025 (Estimated)
Metacrine, Inc. stock logo
MTCR
Metacrine
-$62.21M-$1.03N/AN/AN/A-84.88%-59.33%N/A
XBiotech Inc. stock logo
XBIT
XBiotech
-$24.56M-$1.29N/AN/AN/A-15.99%-14.85%8/11/2025 (Estimated)

Latest MTCR, BHST, ENTA, and XBIT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/29/2025Q1 2025
BioHarvest Sciences Inc. stock logo
BHST
BioHarvest Sciences
-$0.15-$0.13+$0.02-$0.13$7.80 million$7.64 million
5/15/2025Q1 2025
BioHarvest Sciences Inc. stock logo
BHST
BioHarvest Sciences
-$0.15-$0.13+$0.02-$0.13$8.93 million$7.64 million
5/14/2025Q1 2025
XBiotech Inc. stock logo
XBIT
XBiotech
N/A-$0.36N/A-$0.36N/AN/A
5/12/2025Q2 2025
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
-$1.04-$1.06-$0.02-$1.06$15.96 million$14.93 million
3/31/2025Q4 2024
BioHarvest Sciences Inc. stock logo
BHST
BioHarvest Sciences
-$0.12-$0.17-$0.05-$0.17$7.24 million$7.17 million
3/18/2025Q4 2024
XBiotech Inc. stock logo
XBIT
XBiotech
N/A-$0.34N/A-$0.34N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BioHarvest Sciences Inc. stock logo
BHST
BioHarvest Sciences
N/AN/AN/AN/AN/A
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
N/AN/AN/AN/AN/A
Metacrine, Inc. stock logo
MTCR
Metacrine
N/AN/AN/AN/AN/A
XBiotech Inc. stock logo
XBIT
XBiotech
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioHarvest Sciences Inc. stock logo
BHST
BioHarvest Sciences
N/A
0.80
0.48
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
N/A
5.47
5.47
Metacrine, Inc. stock logo
MTCR
Metacrine
0.34
12.15
12.15
XBiotech Inc. stock logo
XBIT
XBiotech
N/A
11.57
11.57

Institutional Ownership

CompanyInstitutional Ownership
BioHarvest Sciences Inc. stock logo
BHST
BioHarvest Sciences
N/A
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
94.99%
Metacrine, Inc. stock logo
MTCR
Metacrine
37.72%
XBiotech Inc. stock logo
XBIT
XBiotech
55.70%

Insider Ownership

CompanyInsider Ownership
BioHarvest Sciences Inc. stock logo
BHST
BioHarvest Sciences
N/A
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
13.89%
Metacrine, Inc. stock logo
MTCR
Metacrine
13.80%
XBiotech Inc. stock logo
XBIT
XBiotech
33.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioHarvest Sciences Inc. stock logo
BHST
BioHarvest Sciences
N/A16.43 millionN/AN/A
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
16021.38 million18.37 millionOptionable
Metacrine, Inc. stock logo
MTCR
Metacrine
1042.57 million36.70 millionNot Optionable
XBiotech Inc. stock logo
XBIT
XBiotech
10030.49 million20.39 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
BioHarvest Sciences stock logo

BioHarvest Sciences NASDAQ:BHST

$6.35 +0.10 (+1.60%)
As of 05/28/2025 03:53 PM Eastern

BioHarvest Sciences Inc. is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications. BioHarvest Sciences Inc. is based in Vancouver, Canada.

Enanta Pharmaceuticals stock logo

Enanta Pharmaceuticals NASDAQ:ENTA

$5.87 +0.05 (+0.86%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$5.86 0.00 (-0.09%)
As of 05/28/2025 06:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Metacrine stock logo

Metacrine NASDAQ:MTCR

Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

XBiotech stock logo

XBiotech NASDAQ:XBIT

$2.91 -0.05 (-1.69%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$2.92 +0.00 (+0.17%)
As of 05/28/2025 04:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.